Summary for doctors
- First line in advanced kidney cancer [1].
- The highest tumour response rate among first-line combinations; but side effects and lenvatinib dose reductions are common [1].
Dose and schedule
Lenvatinib + pembrolizumab
Advanced kidney cancer, first lineEach drug’s schedule in the table
Advanced kidney cancer, first line
| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Lenvatinib | 20 mg once a day | Oral | Daily |
| Pembrolizumab | 200 mg | IV | Every 3 weeks |
Evidence: CLEAR (2021)
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Premedication and supportive care
- Control blood pressure before and during treatment; urine protein.
Monitoring and dose adjustment
- Lenvatinib dose reductions: 14, 10, 8 mg [2]. TSH, glucose, liver enzymes and creatinine at baseline and before each cycle; immune-related toxicity as in the immunotherapy toxicity lesson.
Main evidence
Show detailsHide
Related cancer types
Treatment regimens (physicians)
References
2 referencesShow all references, 1 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2
This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/lenvatinib-pembrolizumab-rcc/